A national study called The Platform Adaptive trial of NOvel antiviRals for eArly treatMent of covid-19 In the Community (PANORAMIC), run by the University of Oxford in close collaboration with GP hubs, has now launched and is recruiting. The UK Antiviral Taskforce has selected all treatments to be tested – the first treatment to be investigated through the trial will be molnupiravir, a COVID antiviral pill already been licensed by the MHRA.
The trial wants to recruit around 10,000 UK patients at risk of serious illness from COVID-19 to have the opportunity to take the treatment molnupiravir at home after receiving a positive PCR test.
From the 16th December, those at highest risk who test positive for the virus will also be able to access molnupiravir or other available community treatments via the COVID Medicines Delivery Unit (CMDU).
Journalists dialled in to this briefing to hear the panel discuss questions such as:
Please note there are no data or results yet – this is just the launch of the study and the start of deployment. This was an opportunity for science journalists to ask their questions to the panel if they have them.
Eddie Gray, Chair of UK Antivirals Taskforce
Prof Chris Butler, Professor of Primary Care, PANORAMIC Chief Investigator, Nuffield Department of Primary Care Health Sciences, University of Oxford
Prof Phil Evans, NIHR CRN National Specialty Lead for Primary Care
Dr David Lowe, Consultant Clinical Immunologist, UCL